Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
10 participants
INTERVENTIONAL
2025-07-30
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
NCT06858319
A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy.
NCT05016323
Study of Belimumab Administered Subcutaneously to Healthy Subjects
NCT01583530
Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy
NCT02433236
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE
NCT01457430
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BHV-1400
BHV-1400
BHV-1400 is delivered subcutaneously (SC)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BHV-1400
BHV-1400 is delivered subcutaneously (SC)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biohaven Therapeutics Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Site-001
Farmington, Connecticut, United States
Site-003
Miami Lakes, Florida, United States
Site-011
Miami Lakes, Florida, United States
Site-005
Pembroke Pines, Florida, United States
Site-008
Lawrenceville, Georgia, United States
Site-009
Hinsdale, Illinois, United States
Site-012
Indianapolis, Indiana, United States
Site-006
Chesterfield, Missouri, United States
Site-002
Dakota Dunes, South Dakota, United States
Site-004
Houston, Texas, United States
Site-007
Leicester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BHV1400-102
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.